SCHEMBL3765084

SCHEMBL3765084

O=C(Cc1ccccc1-c1[c]nccc1)N1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ACHE P22303 1/20 0.40
RBP4 P02753 1/20 0.39
NPC1 O15118 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
ECE2 P0DPD6 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758804 0.99 RBP4 (0.40) HPGDKMT2AALDH1A1GAAHSD17B10
SCHEMBL3756653 0.96 RBP4 (0.40) HPGDKMT2AALDH1A1GAAHSD17B10
SCHEMBL3756488 0.88 FNTA (0.39) KMT2AALDH1A1RBP4KDM4EMEN1
SCHEMBL3769090 0.79 TSHR (0.56) HPGDKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL3758914 0.78 GAA (0.37) KMT2AALDH1A1GAASMN1; SMN2MEN1
SCHEMBL3760644 0.78 TSHR (0.57) KMT2AALDH1A1NPC1SMN1; SMN2MEN1
SCHEMBL3754788 0.78 ALDH1A1 (0.50) KMT2AALDH1A1GAANPC1KDM4E
SCHEMBL3751373 0.76 ALDH1A1 (0.47) ALDH1A1GAANPC1KDM4EL3MBTL1
SCHEMBL3760379 0.75 TSHR (0.54) KMT2AALDH1A1SMN1; SMN2TSHRNPSR1
SCHEMBL3751946 0.74 NR4A2 (0.34) HPGDALDH1A1HSD17B10KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HPGD 3366/4885KMT2A 2175/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.